The size of the Asia Pacific Stem Cell Market is forecasted to grow USD 3641.00 million in 2021 and estimated to reach USD 5863.87 million by the end of 2026, with a CAGR of 10%, during the forecast period.
The growth of the market is mainly driven due to the better regulatory support through encouraging government policies and increasing awareness among the public. The Asia-pacific stem cell market is invested in various research organizations and developments of the stem cell industry. Innovation and implementation of multiple technologies and increasing population continuously in this region are enhancing the demand of the market.
This research report segmented and sub-segmented the Asia Pacific Stem Cell Market into the following categories:
Regional Analysis
The stem cell market of India is anticipated to grow at the compound annual growth rate in upcoming years due to high awareness about stem cell, developments in tissue engineering and increasing patients of chronic and genetic disorders. Also, the market has a substantial segment of pluripotent and embryonic products. Hence the market is growing in this year. The numbers of companies are trying to develop new products in the market.
The Chinese stem cell market has the most significant growth in the Asia-pacific region. Presence of various diseases such as kidney disease, cardiac diseases, haematological diseases, diabetes mellitus, and osteoarthritis is boosting the demand of the market. Also, rapid development in stem cell therapy and its awareness is fuelling the Chinese market growth. China has applied for more stem cell patents for developments and continuous investment in research and development of stem cell. The majority of key players are in China that accounted for the highest share of the stem cell market.
The stem cell market of Japan has projected to grow due to most of the prominent key players focuses on the development of gene therapy. Also, the Japanese health ministry approved fast-track stem cell therapy (Sterimac), and this treatment is available to Japanese people.
Some of the Promising Companies Operating the Asia Pacific Stem Cell Market Profiled in the Report are Athersys, StemCells Inc, Cryo-Cell International, Geron Corporation, Mesoblast Ltd, Aastrom Biosciences Inc, Celgene Corporation, Invitrogen and Cytori Therapeutics Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By mode of treatment
5.1.1 Autologous
5.1.2 Allogeneic
5.2 By application
5.2.1 CNS
5.2.2 CVS
5.2.3 GIT
5.2.4 Regenerative Medicine
5.2.5 Musculoskeletal
5.2.6 Eye & Immune System Development
5.2.7 Blood Disorders
5.3 By technology
5.3.1 Cell Acquisition
5.3.2 Cell Production
5.3.3 Cryopreservation
5.3.4 Expansion
5.3.5 Sub-Culture
5.4 By type
5.4.1 Adult Stem Cells
5.4.2 Human Embryonic Cells
5.4.3 Pluripotent Stem Cell
5.4.4 Natural Rosette Cells
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
